Literature DB >> 8365689

Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal.

G G Sorano1, G Biondi, M Conti, G Mameli, D Licheri, F Marongiu.   

Abstract

The aim of our study was to investigate the effect of a diet with a known vitamin K content on the monitor test for oral anticoagulant therapy. We studied 10 poorly controlled patients (7 women and 3 men, mean age 48 +/- 15 years) in therapy with acenocoumarol for at least 1 year. Another group of 10 poorly controlled patients was considered as a control group. After a baseline period, during which a free diet was allowed, patients were administered a diet with a controlled vitamin K content; in the same period, control subjects were not subjected to any dietary restriction. Thrombotest (Nyegaard, Oslo) was employed for monitoring oral anticoagulant therapy, with a therapeutic range between 2.3 and 4.8 INR. We found a significant difference by thrombotest between the percentages within the therapeutic range obtained before and during dietary treatment (p = 0.0001). The difference in percentages was -0.31 and the 95% CI, of the difference ranged from -0.45 to -0.17. No significant difference was shown in the control group in the same periods. Our data suggest that a diet with a controlled vitamin K content is effective in increasing the percentage of tests within the therapeutic range in patients with poorly controlled anticoagulation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8365689     DOI: 10.1159/000216857

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  8 in total

Review 1.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  High intra- and inter-individual variability of plasma vitamin K concentrations in patients with atrial fibrillation under warfarin therapy.

Authors:  Y-E Kim; H I Woo; Y K On; J S Kim; S-Y Lee
Journal:  Eur J Clin Nutr       Date:  2015-04-01       Impact factor: 4.016

Review 3.  Clinical utilization of the international normalized ratio (INR).

Authors:  R S Riley; D Rowe; L M Fisher
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

4.  Effectiveness of warfarin among patients with cancer.

Authors:  Adam J Rose; Jeff P Sharman; Al Ozonoff; Lori E Henault; Elaine M Hylek
Journal:  J Gen Intern Med       Date:  2007-05-03       Impact factor: 5.128

5.  Genetic and environmental risk factors for oral anticoagulant overdose.

Authors:  C Verstuyft; A Robert; S Morin; M A Loriot; A Flahault; P Beaune; C Funck-Brentano; P Jaillon; L Becquemont
Journal:  Eur J Clin Pharmacol       Date:  2003-02-18       Impact factor: 2.953

6.  Measurement of warfarin in the oral fluid of patients undergoing anticoagulant oral therapy.

Authors:  Silvia Ghimenti; Tommaso Lomonaco; Massimo Onor; Laura Murgia; Aldo Paolicchi; Roger Fuoco; Lucia Ruocco; Giovanni Pellegrini; Maria Giovanna Trivella; Fabio Di Francesco
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

Review 7.  Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.

Authors:  Jonathan Douxfils; Anne Tamigniau; Bernard Chatelain; Catherine Goffinet; Jean-Michel Dogné; François Mullier
Journal:  Thromb J       Date:  2014-11-04

8.  Inappropriate preinjury warfarin use in trauma patients: A call for a safety initiative.

Authors:  H H Hon; A Elmously; C D Stehly; J C Stoltzfus; M A Granson; S P Stawicki; B A Hoey
Journal:  J Postgrad Med       Date:  2016 Apr-Jun       Impact factor: 1.476

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.